Literature DB >> 21251204

T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.

E A James1, S D van Haren, R A Ettinger, K Fijnvandraat, J A Liberman, W W Kwok, J Voorberg, K P Pratt.   

Abstract

BACKGROUND: Development of neutralizing anti-factor (F)VIII antibodies ('inhibitors') is a serious clinical problem in hemophilia A. Increased inhibitor risk has been associated with certain FVIII missense substitutions, including R593C in the A2 domain.
OBJECTIVES: The aim of the present study was to identify T-cell epitopes in FVIII and characterize T-cell responses in two unrelated hemophilia A subjects sharing F8-R593C and HLA-DRB1*1101 genotypes. We hypothesized that the hemophilic substitution site coincides with an important T-cell epitope. PATIENTS/
METHODS: The binding affinities of peptides for recombinant HLA-DR proteins were measured and compared with epitope prediction results. CD4+ T cells were stimulated using peptides and stained with fluorescent, peptide-loaded tetramers.
RESULTS: The inhibitor subjects, but not HLA-matched controls, had high-avidity HLA-DRB1*1101-restricted T-cell responses against FVIII(589-608), which contains the hemophilic missense site. Antigen-specific T cells secreted Th1 and Th2 cytokines and proliferated in response to FVIII and FVIII(592-603). FVIII(589-608) bound with physiologically relevant (micromolar) IC(50) values to recombinant DR0101, DR1101 and DR1501 proteins.
CONCLUSIONS: Hemophilia A patients with R593C missense substitutions and these HLA haplotypes had an increased incidence of inhibitors in our cohorts, supporting a paradigm in which presentation of FVIII epitopes containing the wild-type R593 influences inhibitor risk in this hemophilia A sub-population.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21251204      PMCID: PMC4323178          DOI: 10.1111/j.1538-7836.2011.04202.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  49 in total

Review 1.  Factor VIII inhibitors.

Authors:  L W Hoyer
Journal:  Curr Opin Hematol       Date:  1995-09       Impact factor: 3.284

2.  Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

Authors:  Jan Astermark; Johannes Oldenburg; Anna Pavlova; Erik Berntorp; Ann-Kari Lefvert
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

Review 3.  Genetic risk factors for inhibitors to factors VIII and IX.

Authors:  J Oldenburg; A Pavlova
Journal:  Haemophilia       Date:  2006-12       Impact factor: 4.287

4.  A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.

Authors:  M Jacquemin; A Benhida; K Peerlinck; B Desqueper; L Vander Elst; R Lavend'homme; R d'Oiron; R Schwaab; M Bakkus; K Thielemans; J G Gilles; J Vermylen; J M Saint-Remy
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

Review 5.  The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.

Authors:  Samantha C Gouw; H Marÿke van den Berg
Journal:  Semin Thromb Hemost       Date:  2010-02-18       Impact factor: 4.180

6.  Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.

Authors:  Braden Waters; Mohammad Qadura; Erin Burnett; Rouzbeh Chegeni; Andrea Labelle; Patrick Thompson; Christine Hough; David Lillicrap
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

Review 7.  Autoantibodies to factor VIII.

Authors:  Sébastien Lacroix-Desmazes; Namita Misra; Jagadeesh Bayry; Dipika Mohanty; Srini V Kaveri; Michel D Kazatchkine
Journal:  Autoimmun Rev       Date:  2002-02       Impact factor: 9.754

8.  T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide.

Authors:  E A James; W W Kwok; R A Ettinger; A R Thompson; K P Pratt
Journal:  J Thromb Haemost       Date:  2007-12       Impact factor: 5.824

9.  Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development.

Authors:  Y Repessé; M Slaoui; D Ferrandiz; P Gautier; C Costa; J M Costa; J M Lavergne; A Borel-Derlon
Journal:  J Thromb Haemost       Date:  2007-04-18       Impact factor: 5.824

10.  Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses.

Authors:  Ruth A Ettinger; Eddie A James; William W Kwok; Arthur R Thompson; Kathleen P Pratt
Journal:  Blood       Date:  2009-06-23       Impact factor: 22.113

View more
  22 in total

Review 1.  Inhibitors - cellular aspects and novel approaches for tolerance.

Authors:  D W Scott
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

2.  Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.

Authors:  Devi Gunasekera; Ruth A Ettinger; Shelley Nakaya Fletcher; Eddie A James; Maochang Liu; John C Barrett; Janice Withycombe; Dana C Matthews; Melinda S Epstein; Richard J Hughes; Kathleen P Pratt
Journal:  Blood       Date:  2015-01-23       Impact factor: 22.113

Review 3.  MHC class II tetramers.

Authors:  Gerald T Nepom
Journal:  J Immunol       Date:  2012-03-15       Impact factor: 5.422

Review 4.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

5.  T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.

Authors:  Ruth A Ettinger; Pedro Paz; Eddie A James; Devi Gunasekera; Fred Aswad; Arthur R Thompson; Dana C Matthews; Kathleen P Pratt
Journal:  Blood       Date:  2016-07-28       Impact factor: 22.113

6.  CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.

Authors:  Katharina N Steinitz; Pauline M van Helden; Brigitte Binder; David C Wraith; Sabine Unterthurner; Corinna Hermann; Maria Schuster; Rafi U Ahmad; Markus Weiller; Christian Lubich; Maurus de la Rosa; Hans Peter Schwarz; Birgit M Reipert
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

7.  Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.

Authors:  Weiqing Jing; Juan Chen; Yuanhua Cai; Yingyu Chen; Jocelyn A Schroeder; Bryon D Johnson; Weiguo Cui; Qizhen Shi
Journal:  Blood Adv       Date:  2019-10-22

8.  FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.

Authors:  Ruth A Ettinger; Joseph A Liberman; Devi Gunasekera; Komal Puranik; Eddie A James; Arthur R Thompson; Kathleen P Pratt
Journal:  Blood Adv       Date:  2018-02-27

9.  Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.

Authors:  Margaret V Ragni; Lynn M Malec
Journal:  Expert Rev Hematol       Date:  2014-11-05       Impact factor: 2.929

Review 10.  Progress toward inducing immunologic tolerance to factor VIII.

Authors:  David W Scott; Kathleen P Pratt; Carol H Miao
Journal:  Blood       Date:  2013-03-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.